<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the fact that there are numerous advantages to drug repositioning over the traditional de novo approach, it is not all successful. There have been a few instances where drug repositioning projects have failed. A kinase inhibitor, Bevacizumab, which was, developed to treat gastric cancer, failed to show efficacy in phase III trials despite being well studied and repositioned to several other types of cancers [
 <xref rid="B115-viruses-12-01058" ref-type="bibr">115</xref>]. 
</p>
